Loading...
Loading...
Dose-dependent weight loss of 12.5–14.9% (vs placebo) over 46 weeks in phase 2 obesity trials.
Survodutide is a dual agonist that activates both GLP-1 and glucagon receptors. The GLP-1 component enhances satiety and improves glycemic control, while the glucagon component increases energy expenditure and promotes hepatic lipid oxidation.
Typical Dose
0.6-6mg
A 15-amino-acid peptide derived from human gastric juice with potent tissue-healing and anti-inflammatory properties.
Fertility Preservation: Maintains testosterone and spermatogenesis during TRT.
Potential Benefits: Increases in lean body mass, reductions in adipose tissue, improved metabolic parameters.